A Study of LY3164530 in Participants With Cancer

Inclusion Criteria

- Have advanced or metastatic cancer and be an appropriate candidate for experimental
therapy.

- Have adequate organ function.

- Prior Treatments:

- Systemic treatments: Must have discontinued previous systemic treatments for
cancer and recovered from the acute effects of therapy. Participants must have
discontinued:

- Cytotoxic therapies or targeted agents that are small molecule inhibitors
for 5 half-lives or at least 28 days.

- Mitomycin-C or nitrosourea therapy for at least 42 days and biologic agents
for at least 28 days.

- Radiation therapy and surgery must be completed 4 weeks prior to therapy, except
for limited field radiation therapy, which must be completed 2 weeks before
therapy.

- If participant is of reproductive potential, must agree to use medically approved
contraceptive precautions during the study and for three months following the last
dose of study drug.

- If the participant is a female of childbearing potential, must have had a negative
serum or urine pregnancy test within 14 days of the first dose of study drug and must
not be breast feeding.

Exclusion Criteria:

- Must not have taken an unapproved drug as treatment for any indication within the
last 28 days prior to starting study treatment.

- Must not have an active symptomatic fungal, bacterial or viral infection, including
human immunodeficiency virus (HIV) or Hepatitis A, B, or C.

- Must not have a serious preexisting medical conditions or concomitant disorders.

- Must not have leukemia.

- Must not have QT interval of >470 millisecond.

- Must not have a serious cardiac condition, such as congestive heart failure, unstable
angina pectoris, or heart attack within the last 3 months.